Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec and Cardiokine have agreed to terminate their lixivaptan collaboration, triggering the return of all lixivaptan rights to Cardiokine.
Subscribe to our email newsletter
Biogen Idec said that the step is consistent with its strategic decision to narrow its research and development (R&D) focus and terminate its efforts in cardiovascular medicine that was reached before completion of the Phase 3 development program for lixivaptan.
Lixivaptan, an orally active, vasopressin receptor antagonist, is currently in late stage development for the treatment of hyponatremia.
Lixivaptan is thought to antagonise the action of vasopressin on the V2 receptors in the collecting duct of the kidney, causing excretion of water without loss of sodium or other electrolytes.
Cardiokine president and CEO Amber Salzman said that she was pleased that they have regained exclusive global rights to Lixivaptan.
"We are nearing the completion of the Phase 3 program and look forward to study results and confirming our registration plans in the near future," Salzman said.